Premium
Cholestyramine‐Induced Hyperchloremic Metabolic Acidosis
Author(s) -
Scheel Paul J.,
Whelton Andrew,
Rossiter Kevin,
Watson Alan
Publication year - 1992
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/009127009203200608
Subject(s) - cholestyramine , metabolic acidosis , medicine , concomitant , acidosis , spironolactone , anion gap , diarrhea , anesthesia , cholesterol , aldosterone
Cholestyramine is a nonabsorbable anion exchange resin that is used predominantly for the treatment of hypercholesterolemia in adults and the management of acute diarrhea in children. The authors report two cases of severe hyperchloremic nonanion gap metabolic acidosis associated with the use of cholestyramine therapy. The authors recommend that patients taking cholestyramine who have concomitant renal insufficiency or who are volume depleted or who are taking spironolactone be monitored carefully for the emergence of a hyperchloremic metabolic acidosis.